Visionary Pharmaceuticals, Inc.

Visionary Pharmaceuticals is a privately held biotechnology company based in San Diego, focused on the discovery and development of first-in-class, small molecule oral therapeutics. The company utilizes a proprietary computational platform, including its 'BindingSIGHTs' technology and a Nuclear Receptor and Kinase Knowledge Engine, to accelerate hit finding and lead optimization for challenging drug targets. The company's R&D efforts are primarily directed toward addressing significant unmet medical needs in autoimmune diseases and cancer. Key therapeutic targets include RORγt (relevant for inflammatory bowel disease, arthritis, multiple sclerosis, and psoriasis) and SGK1 (a mediator of chemoresistance in triple-negative breast cancer and other solid tumors).